Paris‑based Ipsen agreed an exclusive licensing deal for SIM‑0613, a preclinical LRRC15‑targeting antibody‑drug conjugate (ADC) developed by Simcere Zaiming, with potential payments totaling roughly $1.06 billion. The ADC showed robust tumor regressions in preclinical models and Ipsen expects to begin a Phase I trial in the second half of next year. Ipsen positioned the transaction as part of a rapid ADC build‑out that adds a tumor‑stroma target expected to address multiple solid tumors. Simcere will collaborate on development while Ipsen handles rights outside Greater China, highlighting continued pharma investment in ADC platforms.